Companies › Biogen
12 active drug programs in 25 registered trials: 12 Phase 3, 7 Phase 1, 5 Phase 2, 1 Phase 4; Neurology, Other, Immunology, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tofersen SOD1 mRNA antisense inhibitor | SOD1 | Phase 4 | Amyotrophic Lateral Sclerosis; Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation; ALS (Amyotrophic Lateral Sclerosis) | May 2027 |
| Felzartamab Lymphocyte differentiation antigen CD38 inhibitor | CD38 | Phase 3 | Antibody-mediated Rejection; Immunoglobulin A Nephropathy (IgAN); Primary Membranous Nephropathy; Graves' Disease … | Dec 2026 |
| Litifilimab (BIIB059) C-type lectin domain family 4 member C inhibitor | CLEC4C | Phase 3 | Lupus Erythematosus, Systemic; Subacute Cutaneous Lupus Erythematosus | Mar 2027 |
| Peginterferon Beta-1A (BIIB017) Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | May 2027 |
| Nusinersen (BIIB058) SMN2 pre-mRNA positive modulator | SMN2 | Phase 3 | Spinal Muscular Atrophy; Muscular Atrophy, Spinal | Sep 2027 |
| Omaveloxolone (BIIB141) Nuclear factor erythroid 2-related factor 2 activator | NFE2L2 | Phase 3 | Friedreich Ataxia | Nov 2027 |
| Salanersen (BIIB115) SMN2 splicing modulator that increases production of functional SMN protein | SMN2 | Phase 3 | Spinal Muscular Atrophy; Muscular Atrophy, Spinal; Healthy Volunteer | Jun 2028 |
| Diranersen Antisense oligonucleotide targeting ATXN2 mRNA | ATXN2 | Phase 2 | Mild Cognitive Impairment Due to Alzheimer's Disease | Jun 2028 |
| BIIB145 | – | Phase 1 | Healthy Volunteer | Feb 2027 |
| BIIB144 | – | Phase 1 | Healthy Volunteer | Jun 2028 |
| BIIB147 | – | Phase 1 | Amyotrophic Lateral Sclerosis | Jan 2034 |
| BIIB142 | – | Phase 1 | Healthy Volunteer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07133828 | BIIB142 | Phase 1 | Healthy Volunteer | Other | Aug 2026 |
| NCT06685757 | Felzartamab | Phase 3 | Antibody-mediated Rejection | Other | Dec 2026 |
| NCT07294144 | Tofersen | Phase 2 | ALS (Amyotrophic Lateral Sclerosis) | Neurology | Jan 2027 |
| NCT07225517 | BIIB145 | Phase 1 | Healthy Volunteer | Other | Feb 2027 |
| NCT04961567 | Litifilimab (BIIB059) | Phase 3 | Lupus Erythematosus, Systemic | Immunology | Mar 2027 |
| NCT04895241 | Litifilimab (BIIB059) | Phase 3 | Lupus Erythematosus, Systemic | Immunology | Mar 2027 |
| NCT03958877 | Peginterferon Beta-1A (BIIB017) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | Neurology | May 2027 |
| NCT07223723 | Tofersen | Phase 4 | Amyotrophic Lateral Sclerosis | Neurology | May 2027 |
| NCT06935357 | Felzartamab | Phase 3 | Immunoglobulin A Nephropathy (IgAN) | Genitourinary | May 2027 |
| NCT04856982 | Tofersen | Phase 3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | Neurology | Aug 2027 |
| NCT05067790 | Nusinersen (BIIB058) | Phase 3 | Spinal Muscular Atrophy | Neurology | Sep 2027 |
| NCT06555419 | Nusinersen (BIIB058) | Phase 1 | Muscular Atrophy, Spinal | Neurology | Sep 2027 |
| NCT06953583 | Omaveloxolone (BIIB141) | Phase 3 | Friedreich Ataxia | Neurology | Nov 2027 |
| NCT05531565 | Litifilimab (BIIB059) | Phase 2 | Subacute Cutaneous Lupus Erythematosus | Immunology | Dec 2027 |
| NCT07722546 | Felzartamab | Phase 2 | Graves' Disease | Metabolic and endocrine | Jan 2028 |
| NCT07219043 | Felzartamab | Phase 2 | Microvascular Inflammation | Immunology | Feb 2028 |
| NCT05399888 | Diranersen | Phase 2 | Mild Cognitive Impairment Due to Alzheimer's Disease | Neurology | Jun 2028 |
| NCT07662148 | BIIB144 | Phase 1 | Healthy Volunteer | Other | Jun 2028 |
| NCT07444476 | Salanersen (BIIB115) | Phase 3 | Spinal Muscular Atrophy | Neurology | Jun 2028 |
| NCT07221669 | Salanersen (BIIB115) | Phase 3 | Muscular Atrophy, Spinal | Neurology | Nov 2028 |
| NCT07444450 | Salanersen (BIIB115) | Phase 3 | Muscular Atrophy, Spinal | Neurology | Jul 2029 |
| NCT06962800 | Felzartamab | Phase 3 | Primary Membranous Nephropathy | Genitourinary | Jan 2030 |
| NCT06054893 | Omaveloxolone (BIIB141) | Phase 1 | Friedreich Ataxia | Neurology | Jun 2030 |
| NCT05575011 | Salanersen (BIIB115) | Phase 1 | Healthy Volunteer | Neurology | Nov 2031 |
| NCT07855211 | BIIB147 | Phase 1 | Amyotrophic Lateral Sclerosis | Neurology | Jan 2034 |
Cash and short-term investments of $1.3bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Novartis Roche Takeda Johnson & Johnson (Janssen) Zhejiang ACEA Pharmaceutical CASI pharmaceuticals Sanofi Celltrion GSK Sinocelltech
Ionis Pharmaceuticals UCB Biopharma SRL Alnylam Pharmaceuticals Praxis Precision Medicines Sarepta Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.